金城医药(300233.SZ)子公司拟向海默尼出售一项药品生产技术及上市许可持有人权益

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and marketing rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of 50 million yuan, which aligns with Jincheng Tail's product development strategy and aims to optimize its product structure and asset efficiency [1][1][1] Group 1 - Jincheng Tail, a wholly-owned subsidiary of Jincheng Pharmaceutical, holds the drug approval number for "Progesterone Vaginal Soft Capsules" (brand name: Langyigengbaifen®) [1] - The total transaction fee for the transfer of rights is 50 million yuan, including tax [1] - The transfer is expected to enhance Jincheng Tail's asset operation efficiency and further optimize its asset structure [1]